

**PEDIATRIX MEDICAL GROUP, INC.**  
**RECONCILIATION OF NET LOSS**  
**TO FORWARD-LOOKING ADJUSTED EBITDA**  
(in thousands)  
(Unaudited)

	<b>Year Ended</b>	
	<b>December 31, 2024</b>	
Net loss	\$ (110,315)	\$ (103,015)
Interest expense	40,559	40,559
Income tax provision	1,990	4,690
Depreciation and amortization expense	31,800	31,800
Transformational and restructuring related expenses	48,000	48,000
Goodwill and long-lived asset impairments	182,034	182,034
Loss on disposal of businesses	10,932	10,932
Adjusted EBITDA	\$ 205,000	\$ 215,000

This reconciliation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on assumptions and assessments made by Pediatrix management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements in this reconciliation are made as of November 1, 2024 and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well Pediatrix's current reports on Form 8-K, filed with the Securities and Exchange Commission.